Article | Published:

Reduced nucleus accumbens enkephalins underlie vulnerability to social defeat stress

Abstract

Enkephalins, endogenous ligands for delta opioid receptors (DORs), are highly enriched in the nucleus accumbens (NAc). They are implicated in depression but their role in the NAc, a critical brain region for motivated behavior, is not fully investigated. To provide insight into enkephalin function we used a chronic social defeat stress paradigm, where animals are either categorized as susceptible or resilient to stress based on their performance in a social interaction test. Compared to controls, susceptible animals showed reduced enkephalin levels in the NAc. Such decrease in enkephalin levels is not due to a change in mRNA of its precursor protein, proenkephalin, in susceptible mice but is consistent with increased mRNA levels of enkephalinases in the NAc of susceptible animals. Systemic administration of enkephalinase inhibitors or NAc infusion of the DOR agonist, SNC80, caused a resilient outcome to CSDS. Both treatments increased phosphorylation of ERK, which was downregulated by social defeat stress. To further validate these results, we also used Q175 knock-in mice, an animal model of Huntington’s disease in which enkephalin levels are reduced in striatum and comorbidity with mood disorders is common. Consistent with data in wild-type mice, Q175 animals showed reduced enkephalin levels in the NAc and enhanced susceptibility to a social defeat stress. Overall, our data implicate that depression­like behavior induced by social defeat stress arises from disrupted DOR signaling resulting from lowered levels of enkephalins, which is partly mediated through elevated expression of enkephalinases.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Mansour A, Hoversten MT, Taylor LP, Watson SJ, Akil H. The cloned μ, δ and κ receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res. 1995;700:89–98.

  2. 2.

    Belluzzi JD, Grant N, Garsky V, Sarantakis D, Wise CD, Stein L. Analgesia induced in vivo by central administration of enkephalin in rat. Nature. 1976;260:625–6.

  3. 3.

    Perrine SA, Hoshaw BA, Unterwald EM. Delta opioid receptor ligands modulate anxiety-like behaviors in the rat. Br J Pharmacol. 2006;147:864–72.

  4. 4.

    Konig M, Zimmer AM, Steiner H, Holmes P V., Crawley JN, Brownstein MJ, et al. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature. 1996;383:535–8.

  5. 5.

    Filliol D, Ghozland S, Chluba J, Martin M, Matthes HWD, Simonin F, et al. Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet. 2000;25:195–200.

  6. 6.

    Jutkiewicz EM, Torregrossa MM, Sobczyk-Kojiro K, Mosberg HI, Folk JE, Rice KC, et al. Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects. Eur J Pharmacol. 2006;531:151–9.

  7. 7.

    Tejedor-Real P, Micó JA, Maldonado R, Roques BP, Gibert-Rahola J. Effect of mixed (RB 38A) and selective (RB 38B) inhibitors of enkephalin degrading enzymes on a model of depression in the rat. Biol Psychiatry. 1993;34:100–7.

  8. 8.

    Germain L, Chouinard G. Treatment of recurrent unipolar major depression with captopril. Biol Psychiatry. 1988;23:637–41.

  9. 9.

    Le Merrer J, Becker JAJ, Befort K, Kieffer BL. Reward processing by the opioid system in the brain. Physiol Rev. 2009;89:1379–412.

  10. 10.

    Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, Walker JM. Endogenous opioids: biology and function. Annu Rev Neurosci. 1984;7:223–55.

  11. 11.

    Snyder SH, Pasternak GW. Historical review: opioid receptors. Trends Pharmacol Sci. 2003;24:198–205.

  12. 12.

    Rossier J, Guillemin R, Bloom F. Foot shock induced stress decreases Leu5-enkephalin immunoreactivity in rat hypothalamus. Eur J Pharmacol. 1978;48:465–6.

  13. 13.

    Nabeshima T, Katoh A, Wada M, Kameyama T. Stress-induced changes in brain Met-enkephalin, Leu-enkephalin and dynorphin concentrations. Life Sci. 1992;51:211–7.

  14. 14.

    de Felipe MDC, Jiménez I, Castro A, Fuentes JA. Antidepressant action of imipramine and iprindole in mice is enhanced by inhibitors of enkephalin-degrading peptidases. Eur J Pharmacol. 1989;159:175–80.

  15. 15.

    Li W, Papilloud A, Lozano-Montes L, Zhao N, Ye X, Zhang X, et al. Stress impacts the regulation neuropeptides in the rat hippocampus and prefrontal cortex. Proteomics. 2018;18:1–10.

  16. 16.

    Gerfen CR, Scott Young W. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res. 1988;460:161–7.

  17. 17.

    Lobo MK, Karsten SL, Gray M, Geschwind DH, Yang XW. FACS-array profiling of striatal projection neuron subtypes in juvenile and adult mouse brains. Nat Neurosci. 2006;9:443–52.

  18. 18.

    Knoll AT, Carlezon WA. Dynorphin, stress, and depression. Brain Res. 2010;1314:56–73.

  19. 19.

    Krishnan V, Han M-H, Graham DL, Berton O, Renthal W, Russo SJ, et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell. 2007;131:391–404.

  20. 20.

    Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rev Neurosci. 2013;625:609–25.

  21. 21.

    Lobo MK, Zaman S, Damez-Werno DM, Koo JW, Bagot RC, DiNieri JA, et al. ΔFosB induction in striatal medium spiny neuron subtypes in response to chronic pharmacological, emotional, and optogenetic stimuli. J Neurosci. 2013;33:18381–95.

  22. 22.

    Chandra R, Francis TC, Konkalmatt P, Amgalan A, Gancarz AM, Dietz DM, et al. Opposing role for Egr3 in nucleus accumbens cell subtypes in cocaine action. J Neurosci. 2015;35:7927–37.

  23. 23.

    Hikida T, Kimura K, Wada N, Funabiki K, Nakanishi S. Distinct roles of synaptic transmission in direct and indirect striatal pathways to reward and aversive behavior. Neuron. 2010;66:896–907.

  24. 24.

    Kravitz AV, Tye LD, Kreitzer AC. Distinct roles for direct and indirect pathway striatal neurons in reinforcement. Nat Neurosci. 2012;15:816–8.

  25. 25.

    Carlezon WA, Thomas MJ. Biological substrates of reward and aversion: A nucleus accumbens activity hypothesis. Neuropharmacology. 2009;56:122–32.

  26. 26.

    Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science. 2006;311:864–8.

  27. 27.

    Francis TC, Chandra R, Friend DM, Finkel E, Dayrit G, Miranda J, et al. Nucleus accumbens medium spiny neuron subtypes mediate depression-related outcomes to social defeat stress. Biol Psychiatry. 2015;77:212–22.

  28. 28.

    Chandra R, Francis TC, Nam H, Riggs LM, Engeln M, Rudzinskas S, et al. Reduced Slc6a15 in nucleus accumbens D2-neurons underlies stress susceptibility. J Neurosci. 2017;37:6527–38.

  29. 29.

    Fox, ME, Chandra R, Menken MS, Larkin EJ, Nam H, Engeln M, et al. Dendritic remodeling of D1 neurons by RhoA/Rho-kinase mediates depression-like behavior. Mol. Psychiatry. 2018. https://doi.org/10.1038/s41380-018-0211-5

  30. 30.

    Donahue RJ, Landino SM, Golden SA, Carroll FI, Russo SJ, Carlezon WA. Effects of acute and chronic social defeat stress are differentially mediated by the dynorphin/kappa-opioid receptor system. Behav Pharmacol. 2015;26:654–63.

  31. 31.

    Menalled LB, Kudwa AE, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N, et al. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington’s disease: ZQ175. PLoS ONE. 2012;7:e49838.

  32. 32.

    Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL. Neuropsychiatric aspects of Huntington’s disease. J Neurol Neurosurg Psychiatry. 2001;71:310–4.

  33. 33.

    Julien CL, Thompson JC, Wild S, Yardumian P, Snowden JS, Turner G, et al. Psychiatric disorders in preclinical Huntington’s disease. J Neurol Neurosurg Psychiatry. 2007;78:939–43.

  34. 34.

    Frank S. Treatment of Huntington’s disease. Neurotherapeutics. 2014;11:153–60.

  35. 35.

    Covey DP, Dantrassy HM, Zlebnik NE, Gildish I, Cheer JF. Compromised dopaminergic encoding of reward accompanying suppressed willingness to overcome high effort costs is a prominent prodromal characteristic of the Q175 mouse model of Huntington’s disease. J Neurosci. 2016;36:4993–5002.

  36. 36.

    Covey DP, Dantrassy HM, Yohn SE, Castro A, Conn PJ, Mateo Y, et al. Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington’s disease. Neuropsychopharmacology. 2018;43:2056–63.

  37. 37.

    Ade KK, Wan Y, Chen M, Gloss B, Calakos N. An improved BAC transgenic fluorescent reporter line for sensitive and specific identification of striatonigral medium spiny neurons. Front Syst Neurosci. 2011;5:1–9.

  38. 38.

    Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB, et al. A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature. 2003;425:917–25.

  39. 39.

    Lindberg I, Smythe SJ, Dahl JL. Regional distribution of enkephalin in bovine brain. Brain Res. 1979;168:200–4.

  40. 40.

    Lindberg I, Dahl JL. Characterization of Enkephalin Release from Rat Striatum. J Neurochem. 1981;36:506–12.

  41. 41.

    Chandra R, Engeln M, Schiefer C, Patton MH, Martin JA, Werner CT, et al. Drp1 mitochondrial fission in D1 neurons mediates behavioral and cellular plasticity during early cocaine abstinence. Neuron. 2017;96:1327–41.e6.

  42. 42.

    Tejedor-Real P, Mico JA, Maldonado R, Roques BP, Gibert-Rahola J. Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacol Biochem Behav. 1995;52:145–52.

  43. 43.

    Jia MR, Wei T, Xu WF. The analgesic activity of Bestatin as a potent APN inhibitor. Front Neurosci. 2010;4:1–10.

  44. 44.

    Bertran-Gonzalez J, Bosch C, Maroteaux M, Matamales M, Herve D, Valjent E, et al. Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J Neurosci. 2008;28:5671–85.

  45. 45.

    Poulin JF, Laforest S, Drolet G. Enkephalin downregulation in the nucleus accumbens underlies chronic stress-induced anhedonia. Stress. 2014;17:88–96.

  46. 46.

    Henry MS, Bisht K, Vernoux N, Gendron L, Torres-Berrio A, Drolet G, et al. Delta opioid receptor signaling promotes resilience to stress under the repeated social defeat paradigm in mice. Front Mol Neurosci. 2018;11:1–15.

  47. 47.

    Ben Natan L, Chaillet P, Lecomte J-M, Marcais H, Uchida G, Costentin J. Involvement of endogenous enkephalins in the mouse ‘behavioral despair’ test. Eur J Pharmacol. 1984;97:301–4.

  48. 48.

    Turner AJ, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J. 1997;11:355–64.

  49. 49.

    Pal Khaket T, Singh J, Attri P, Dhanda S. Enkephalin degrading enzymes: metalloproteases with high potential for drug development. Curr Pharm Des. 2012;18:220–30.

  50. 50.

    Karsten SL, Sang TK, Gehman LTT, Chatterjee S, Liu J, Lawless GM, et al. A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of Tau-induced neurodegeneration. Neuron. 2006;51:549–60.

  51. 51.

    Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011;115:1363–81.

  52. 52.

    Shirayama Y, Chen AC-H, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci. 2002;22:3251–61.

  53. 53.

    Wook Koo J, Labonté B, Engmann O, Calipari ES, Juarez B, Lorsch Z, et al. Essential Role of mesolimbic brain-derived neurotrophic factor in chronic social stress-induced depressive behaviors. Biol Psychiatry. 2016;80:469–78.

  54. 54.

    Kramer HK, Simon EJ. mu and delta-opioid receptor agonists induce mitogen-activated protein kinase (MAPK) activation in the absence of receptor internalization. Neuropharmacology. 2000;39:1707–19.

  55. 55.

    Blomeley CP, Bracci E. Opioidergic interactions between striatal projection neurons. J Neurosci. 2011;31:13346–56.

  56. 56.

    Svingos AL, Clarke CL, Pickel VM. Cellular sites for activation of δ-opioid receptors in the rat nucleus accumbens shell: relationship with Met5-enkephalin. J Neurosci. 1998;18:1923–33.

  57. 57.

    Laurent V, Leung B, Maidment N, Balleine BW. μ- and δ-opioid-related processes in the accumbens core and shell differentially mediate the influence of reward-guided and stimulus-guided decisions on choice. J Neurosci. 2012;32:1875–83.

  58. 58.

    Creed M, Ntamati NR, Chandra R, Lobo MK, Luscher C. Convergence of reinforcing and anhedonic cocaine effects in the ventral pallidum. Neuron. 2016;92:214–26.

  59. 59.

    Covington H, Miczek K. Repeated social-defeat stress, cocaine or morphine. Psychopharmacol (Berl). 2001;158:388–98.

  60. 60.

    Yap JJ, Chartoff EH, Holly EN, Potter DN, Carlezon WA, Miczek KA. Social defeat stress-induced sensitization and escalated cocaine self-administration: the role of ERK signaling in the rat ventral tegmental area. Psychopharmacol (Berl). 2015;232:1555–69.

  61. 61.

    Covington HE, Maze I, Sun H, Bomze HM, DeMaio KD, Wu EY, et al. A role for repressive histone methylation in cocaine-induced vulnerability to stress. Neuron. 2011;71:656–70.

  62. 62.

    Ding JB, Guzman JN, Peterson JD, Goldberg JA, Surmeier DJ. Thalamic gating of corticostriatal signaling by cholinergic interneurons. Neuron. 2010;67:294–307.

  63. 63.

    McGinty JF. Co-localization of GABA with other neuroactive substances in the basal ganglia. Prog Brain Res. 2007;160:273–84.

  64. 64.

    Armario A, Nadal R. Individual differences and the characterization of animal models of psychopathology: a strong challenge and a good opportunity. Front Pharmacol. 2013;4:1–13.

  65. 65.

    Vaugeois JM, Passera G, Zuccaro F, Costentin J. Individual differences in response to imipramine in the mouse tail suspension test. Psychopharmacol (Berl). 1997;134:387–91.

  66. 66.

    Lutz PE, Kieffer BL. Opioid receptors: distinct roles in mood disorders. Trends Neurosci. 2013;36:195–206.

  67. 67.

    Al-Hasani R, McCall JG, Shin G, Gomez AM, Schmitz GP, Bernardi JM, et al. Distinct subpopulations of nucleus accumbens dynorphin neurons drive aversion and reward. Neuron. 2015;87:1063–77.

  68. 68.

    Augood SJ, Faull RLM, Love DR, Emson PC. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington’s disease: a detailed cellular in situ hybridization study. Neuroscience. 1996;72:1023–36.

  69. 69.

    Bissonnette S, Vaillancourt M, Hébert SS, Drolet G, Samadi P. Striatal pre-enkephalin overexpression improves Huntington’s disease symptoms in the R6/2 mouse model of Huntington’s disease. PLoS ONE. 2013;8:e75099.

  70. 70.

    Cepeda C, Wu N, André VM, Cummings DM, Levine MS. The corticostriatal pathway in Huntington’s disease. Prog Neurobiol. 2007;81:253–71.

  71. 71.

    Wang H, Pickel VM. Preferential cytoplasmic localization of delta-opioid receptors in rat striatal patches: comparison with plasmalemmal mu-opioid receptors. J Neurosci. 2001;21:3242–50.

  72. 72.

    Parent A, Sato F, Wu Y, Gauthier J, Lévesque M, Parent M. Organization of the basal ganglia: the importance of axonal collateralization. Trends Neurosci. 2000;23:20–7.

  73. 73.

    Massaly N, Copits BA, Wilson-Poe AR, Hipólito L, Markovic T, Yoon HJ, et al. Pain-induced negative affect is mediated via recruitment of the nucleus accumbens kappa opioid system. Neuron. 2019;102:1–10.

Download references

Acknowledgements

We thank Dr. Iris Lindberg (UMSOM) for her generous donation of anti-Leu- and Met-Enkephalin antisera. We thank Dr. Eric Nestler (ICAHN School of Medicine at Mount Sinai) for reagents used in this study.

Author information

Correspondence to Mary Kay Lobo.

Supplementary information

Supplemental Figures

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5